Diagnostic Pathology Series

[Adriene]

Thesite is secure.

The ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Aims: Somatic genetic testing in non-squamous, non-small cell lung carcinoma (NSCLC) patients is required to highlight subgroups eligible for a number of novel oncological therapies. This study aims to determine whether turnaround times for reporting epidermal growth factor receptors (EGFR) by next-generation sequencing (NGS) alone is sufficient to meet the needs of lung cancer patients.

Methods: We performed a retrospective case series with follow-up. Outcomes of EGFR testing (102 tests) in 96 patients by NGS were compared with a rapid, fully automated PCR-based platform (Idylla) in local histopathology laboratories.

Results: Turnaround time for reporting NGS was 17 calendar days. Reporting using the Idylla EGFR Mutation Test, by contrast, gave a potential turnaround time of 3.8 days from request to authorisation. Three-quarters of patients presenting with stage IV disease had a performance status of 0, 1, or 2 but 18% experienced rapid clinical deterioration (p

Conclusions: We discuss issues around integrating rapid PCR testing alongside NGS in multidisciplinary care pathways and strategies for mitigating against foreseeable difficulties. Dual testing for stage IV non-squamous, NSCLC patients has the potential to improve care and survival outcomes by providing access to the right test at the right time.

This series is applicable to practicing pathologists, surgeons, oncologists, pathologists' assistants, and pathologists-in-training. Healthcare professionals who work in other areas of research and diagnostic surgical pathology will also find these sessions beneficial.

Instructional techniques will include didactic lectures with visual support and case-based discussions. Learners will have an opportunity to interact via an audience response system, as well as participate in question-and-answer sessions to address issues relevant to their own practice and learning needs.

Covering all aspects of molecular pathology as it relates to the transformation and pathogenesis of cancer, this award-winning volume in the Diagnostic Pathology series is an expert resource for pathologists at all levels of experience and training, both as a quick reference and as an efficient review to improve knowledge and skills. This easily accessible, point-of-care reference features templated, bulleted content that is generously illustrated with charts, graphs, tables, and color photomicrographs of histology with special stains.

Dr. Folpe attended Amherst College (Amherst, MA) as an undergraduate, the University of Rochester (Rochester, NY) as a medical student, and performed his residency in Anatomic Pathology at the University of Washington Medical Center (Seattle, WA). Dr. Folpe received additional fellowship training in Immunohistochemistry, under the direction of Dr. Allen Gown, and in Soft Tissue Pathology, under the direction of Dr. Sharon Weiss.

Dr. Folpe is the author of over 250 medical publications, principally in the areas of soft tissue pathology and diagnostic immunohistochemistry, the co-author of the 6th edition and 7th editions of Enzinger and Weiss' Soft Tissue Tumors, co-author of Series 4 of the Armed Forces Institute of Pathology Fascicle on Soft Tissue Tumors, co-author of the 1st and 2nd editions of Bone and Soft Tissue Pathology: A Volume in the Foundations in Diagnostic Pathology Series, and a member of the consensus conferences and editorial boards for the 3rd, 4th and 5th editions of the WHO Classification of Tumors of Soft Tissue and Bone. Dr. Folpe is Co-Chair of the Mayo Clinic Cancer Center Sarcoma Disease Group and co-Director of the Mayo Clinic Bone and Soft Tissue Pathology Fellowship. He is the Bone and Soft Tissue Associate Editor of Modern Pathology, also serves on the editorial boards of numerous other pathology and dermatopathology journals. Dr. Folpe has lectured widely on various aspects of soft tissue pathology and diagnostic immunohistochemistry.

Reference key information quickly and easily with a consistent, user-friendly format and at-a-glance boxes and tables throughout the text. Recognize all the nuances of how pathological lesions present through over 800 full-color illustrations. Practice with confidence and overcome your toughest challenges with advice from the top minds in neuropathology. Make optimal use of the latest approaches for diagnosing fat and air emboli, vascular diseases, trauma, congenital malformations, perinatal diseases and phacomatoses, demyelinating and dysmyelinating disorders, neurodegenerative diseases, infections, metabolic and toxic disorders, glial and non-glial tumors, skeletal muscle and peripheral nerve disorders, and more. Prepare for the future of neuropathology with a new information dedicated to neurotransmitters as they relate to diseases such as Parkinson's and the development of new drugs for these disorders. Apply the latest molecular diagnostic techniques to recognize tumor entities added to the most recent WHO classification of tumors of the central nervous system. Access the fully searchable text online at www.expertconsult.com, along with a downloadable image bank, illustrations, boxes, tables, and more. A quick and easy to use reference, as a refresher or for those just starting out, on neuropathology.

In training and updating, there are two major types of assumptions to knowledge: the vertical path, which gives the deepest foundations to a cognizance to make it reach the highest new frontiers on the specific topic, and the transversal knowledge, which relates different subjects for broaden the field of acquaintance and improve clinical reasoning, also increasing application capabilities.

It means that, if you really want to become an expert in diagnostic imaging of heart and vessels, you need to know well not only the consolidated and up-to-date clinic, together with consolidated and advanced techniques and procedures, but also the pathological and pathophysiological premises to cardiovascular diseases.

This volume is part of a Diagnostic Pathology series, applied in this case to the cardiovascular system. The quality and the success of the publication can be clearly evidenced from the fact that this is the third edition, after the initial of 2013 and the second one, published in 2018. This means that this is a successful book, renewed every 5 years with two major aims: (1) to consolidate the material already known, with an updated information obtained thanks to the new available tools, and (2) to enrich your knowledge with new acquisitions, made possible not only by new techniques, but also by the global progress of research in the cardiovascular field.

All the aspects of cardiovascular pathology are covered, including new cardiac devices, molecular panels and genetics, the latest tumor classifications, up-to-date COVID-19 information, and imaging. Furthermore, the publication includes an eBook allowing to access text, figures, and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud.

The editors are worldwide well-known experts: Dylan V. Miller, Director of Electron Microscopy and Immunostains, Intermountain Central Laboratory, and Monica P. Revelo, Medical Director of Renal and Cardiovascular Pathology, ARUP Laboratories, both Professors of Pathology, University of Utah School of Medicine, Salt Lake City. They have invited to collaborate specialists in each specific field to contribute to the construction of a complete and in-depth work, at the same time easy to read to learn the subject or find an answer to your questions. For this reason, this publication represents a solid tool to know or increase the basis of cardiac pathology not only for experts and postgraduates of the subject, but also for those, clinicians or diagnostic imagers in cardiovascular diseases, who want to better understand the basis of their profession.

Sarcomas are rare malignant tumors. Accurate initial histological diagnosis is essential for adequate management. We prospectively assessed the medical management of all patients diagnosed with sarcoma in a European region over a one-year period to identify the quantity of first diagnosis compared to central expert review (CER).

Histological data of all patients diagnosed with sarcoma in Rhone-Alpes between March 2005 and Feb 2006 were collected. Primary diagnoses were systematically compared with second opinion from regional and national experts.

Over 45% of first histological diagnoses were modified at second reading, possibly resulting in different treatment decisions. Systematic second expert opinion improves the quality of diagnosis and possibly the management of patients.

Second opinion in diagnostic pathology has recently received considerable attention as a result of efforts to enhance institutional performance and reduce medical errors [11]. However, the mechanisms by which second opinion is obtained greatly influence the results [12]. Second opinions given by another institution or a specialty panel at the time of patient referral produce highly discordant rates as compared to analysis of cases referred to experts for review [13]. In the case of expert review, discrepancies are not viewed as "errors" but as a reflection of the acknowledged need for assistance. For this we initiated an exhaustive, prospective study involving the systematic comparison of initial histological diagnosis by a first ('non-expert') pathologist and second opinion (SO) from regional and/or national experts of the disease in a comprehensive population of patients diagnosed in a precise geographical region over a one-year period.

The main objective of the present work was to evaluate the benefit of systematic central review by regional and national experts of all sarcoma cases diagnosed in the Rhne-Alpes region (RA). All sarcoma cases diagnosed by pathologists of the region were reported, and data were statistically analyzed to quantify inter-observer differences and determine their nature.

3a8082e126